TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25900065
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab 1600 mg
Study: 26947201
Drug: Intravenous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab 500 mg/m(2)
Study: 350491
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide
Study: 22674243
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 1% procaine HCl
Study: 22674243
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 0.09% saline (placebo)
Study: 16719158
Drug: Recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant growth hormone (rGH) treatment
Study: 16719158
Drug: No rGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rGH treatment (Control Group)
Study: 12534607
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate mousse (BVM) applied twice daily for 4 weeks
Study: 12534607
Drug: Standard therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapies (ST) applied once or twice daily for 4 weeks
Study: 11067784
Drug: White blood
Normalized name: Human white blood cell product
Approvals — FDA: no, EMA: no, PMDA: no
Description: White blood cell count 0 to 5x10(9)/L
Study: 11067784
Drug: White blood
Normalized name: Human white blood cell product
Approvals — FDA: no, EMA: no, PMDA: no
Description: White blood cell count 5 to 10x10(9)/L
Study: 11067784
Drug: White blood
Normalized name: Human white blood cell product
Approvals — FDA: no, EMA: no, PMDA: no
Description: White blood cell count 10 to 15x10(9)/L
Study: 11067784
Drug: White blood
Normalized name: Human white blood cell product
Approvals — FDA: no, EMA: no, PMDA: no
Description: White blood cell count >15x10(9)/L
Study: 8860884
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg daily oral progesterone
Study: 8860884
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily vaginal progesterone
Study: 1292916
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg, b.i.d.)
Study: 1292916
Drug: Midecamycin acetate
Normalized name: Midecamycin acetate
DrugBank: Midecamycin (DB13456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midecamycin acetate (600 mg, b.i.d.)
Study: 6430768
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISDN (isosorbide dinitrate) acute administration
Study: 6430768
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISDN (isosorbide dinitrate) long-term treatment (40 mg four times daily)
Study: 6430768
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg sublingually-administered nitroglycerin (GTN)
Study: 19106238
Drug: 200 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g/d of a dairy drink with 5.8 mg IPP and 4.4 mg VPP
Study: 19106238
Drug: 100 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/d of a dairy drink with 2.7 mg IPP, 1.9 mg VPP, and 350 mg added K
Study: 15834843
Drug: Nabilone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (2 mg/day)
Study: 9583393
Drug: Intravenous line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous line placement with intradermal saline + benzyl alcohol (0.9%)
Study: 9583393
Drug: Intravenous line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous line placement with intradermal lidocaine (1%)
Study: 2000823
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg beta-carotene/d
Study: 25450123
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy dedicated to the residual limb
Study: 21493732
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 + 10 mg)
Study: 10328392
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous platelet concentrate (APC) during surgery
Study: 27896711
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg)
Study: 27896711
Drug: TOCAS monotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TOCAS monotherapy
Study: 26271567
Drug: Pathogenetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogenetic therapy with antihypoxant reamberin (N=64)
Study: 26271567
Drug: Pathogenetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogenetic therapy with antihypoxant reamberin and hepatoprotector remaxol (N=84)
Study: 19188252
Drug: Rapamycin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin treatment prior to exercise
Study: 15530681
Drug: Influenza and
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza and pneumococcal vaccine
Study: 11586492
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day, n = 14)
Study: 8572850
Drug: Indapamide IR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide IR 2.5 mg
Study: 8572850
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 2.0 mg
Study: 8572850
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 2.5 mg
Study: 2500368
Drug: Semipermanent vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semipermanent vascular access catheters (VACs) maintained without occlusive dressings, antibiotics, repeated flushings or heparin.
Study: 966146
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered methotrimeprazine
Study: 28017546
Drug: 1% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prilocaine (Xylonaest) in combination with epinephrine 1:100,000
Study: 28017546
Drug: Ropivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (10 mg Naropin, 5 ml sodium chloride, 1 ml epinephrine)
Study: 23295794
Drug: Tremelimumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (15 mg/kg once every 90 days)
Study: 23295794
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy (temozolomide or dacarbazine)
Study: 19762088
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.2mg/kg every 6h) with nebulized L-epinephrine (0.5mg/kg every 4h)
Study: 19762088
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.2mg/kg every 6h) without nebulized L-epinephrine
Study: 19762088
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups received nebulized or intravenous isotonic saline solution, or both
Study: 16913269
Drug: H1-antihistamine (loratadine)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-antihistamine (loratadine) + intranasal glucocorticosteroid (mometasone furoate)
Study: 16913269
Drug: Intranasal glucocorticosteroid
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glucocorticosteroid (mometasone furoate) alone
Study: 15605620
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract STW 3-VI 900 mg once daily
Study: 9021907
Drug: MgSO4 infusion
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 infusion
Study: 11771826
Drug: MgSO4 and
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 and GIK infusion after 10 hours
Study: 9027913
Drug: Antimalarial chemoprophylaxis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial chemoprophylaxis in primigravidae
Study: 8098059
Drug: Taxotere 6-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere 6-hour infusion at a maximally tolerated dose of 100 mg/m2
Study: 8098059
Drug: Taxotere 2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere 2-hour infusion at a maximally tolerated dose of 115 mg/m2
Study: 30544179
Drug: Spirited Life
Normalized name: TURPENTINE SPIRITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirited Life wellness intervention including a 10-week online weight-loss program and monthly health coaching for 24 months
Study: 21706145
Drug: romiplostim (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: romiplostim (3 μg/kg weekly for 12 weeks)
Study: 1591091
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment for 5 years
Study: 11823690
Drug: 5-fluorouracil (5-FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU), 600 mg/m2 (arm I)
Study: 11823690
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 500 mg/m2 intravenous bolus and interferon-alpha, 5 MU subcutaneously, three times a week (arm II)
Study: 11823690
Drug: Leucovorin 200
Normalized name: leucovorin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 200 mg/m2 in 2-hour infusion and 5-FU 500 mg/m2 intravenous bolus (arm III)
Study: 171161
Drug: Intragastric fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Study: 171161
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Study: 25197737
Drug: Game-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Game-based oral health education (snakes and ladders game combined with flash cards)
Study: 25197737
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral health education (flash cards once daily for 7 days)
Study: 25603438
Drug: Nepafenac ophthalmic
Normalized name: nepafenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac ophthalmic suspension 0.1%
Study: 9615303
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy for 12 months
Study: 2481787
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg/day)
Study: 1982059
Drug: Celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200 mg/day)
Study: 2684023
Drug: Terbinafine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 500 mg daily for 6 weeks
Study: 2684023
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg daily for 6 weeks
Study: 1097740
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral medrogestone twice daily
Study: 1097740
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg oral medrogestone twice daily
Study: 28939427
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of bacterial endotoxin lipopolysaccharide (LPS) at a dose of 2ng/kg body weight
Study: 28939427
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of bacterial endotoxin lipopolysaccharide (LPS)
Study: 21415778
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg daily alone (G)
Study: 21415778
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus daily oral UFT (GU)
Study: 18316792
Drug: Docetaxel (DOC)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DOC) 75 mg/m² IV every 14 days for four cycles followed by doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC) IV every 14 days for four cycles
Study: 18316792
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC) IV every 14 days for four cycles followed by Docetaxel (DOC) 75 mg/m² IV every 14 days for four cycles
Study: 17159108
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D 4,000 IU/day (adults)
Study: 17159108
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D 400 IU/day (adults)
Study: 17159108
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D 2,000 IU/day (children/adolescents)
Study: 17159108
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D 2,000 IU/day (children/adolescents)
Study: 15251831
Drug: D‐chiro‐inositol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐chiro‐inositol 600 mg orally once daily for 6 to 8 weeks
Study: 2292637
Drug: Pharmacotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy only (NoCT)
Study: 30888253
Drug: Zinc (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (50 mg)
Study: 30888253
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 µg)
Study: 14641691
Drug: 300 micro
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micro g nasal 17beta‐estradiol
Study: 11053333
Drug: L-NMMA after
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA after exercise
Study: 11053333
Drug: L-NMMA after
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA after sham
Study: 9209787
Drug: Ceftibuten (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (400 mg daily)
Study: 9209787
Drug: Amoxicillin/clavulanate (AMX/CA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (AMX/CA, 500 mg/125 mg three times daily)
Study: 9209787
Drug: Ceftibuten (once-daily)
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten (once-daily)
Study: 9209787
Drug: Ceftibuten (twice-daily)
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten (twice-daily)
Study: 7963779
Drug: Clonidine 0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.150 mg i.v.
Study: 7963779
Drug: Meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 50 mg i.v.
Study: 31501493
Drug: Telmisartan with
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan with placebo capsules
Study: 18285411
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/d) for 16 weeks
Study: 11944023
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (400 IU of vitamin E, 500 mg of vitamin C, and 12 mg of beta-carotene daily)
Study: 11944023
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (800 IU of vitamin E, 1000 mg of vitamin C, and 24 mg of beta-carotene daily)
Study: 9743957
Drug: HIT'88/'89 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIT'88/'89 regimen (preradiation chemotherapy)
Study: 9743957
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (CCNU, cisplatin, and vincristine after radiation therapy)
Study: 8983939
Drug: Rifampicine Generic
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicine Generic 300 mg capsules
Study: 8983939
Drug: Rimactan 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimactan 300 mg capsules
Study: 2517005
Drug: Rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1 mg once or twice daily)
Study: 2517005
Drug: Clonidine (0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.150 mg once or twice daily)
Study: 2517005
Drug: Rilmenidine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (single dose)
Study: 9553683
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation
Study: 7325577
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin administered six hours after blockade
Study: 7325577
Drug: 3000 ml
Normalized name: TPN Bag 3000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 ml fluid infusion during operation
Study: 25056584
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with 300 index of reactivity mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for 12 months
Study: 22135048
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry powder at 60 g/d
Study: 22135048
Drug: Freeze-dried strawberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried strawberry powder at 30 g/d
Study: 9661605
Drug: Lipid (Liposyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid (Liposyn II; 1.5 mL/min) and heparin (0.4 U/kg.min; L/H) infusion
Study: 9661605
Drug: Saline/glycerol (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/glycerol (2.25 g/h; S/G) infusion
Study: 2745669
Drug: Bromocriptine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine administration during days 2-12 of ovarian hyperstimulation
Study: 31633607
Drug: Levobupivacaine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.4 mg/kg with volume adjusted to 0.2 mL/kg of 0.2% or 0.4 mL/kg of 0.1%
Study: 31633607
Drug: Levobupivacaine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.4 mg/kg
Study: 31633607
Drug: Levobupivacaine dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine dosing regimen
Study: 27415645
Drug: PRB exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRB exercises combined with motivational group discussions twice weekly for 3 months
Study: 26721137
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (0.3 g ibuprofen orally twice a day for 10 days)
Study: 23320605
Drug: Selenium at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium at 0.15 mg kg(‐1)
Study: 23320605
Drug: Selenium at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium at 0.30 mg kg(‐1)
Study: 23320605
Drug: Selenium at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium at 0.45 mg kg(‐1)
Study: 23320605
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg kg(‐1) selenium)
Study: 19397687
Drug: Polymerized-Collagen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymerized-Collagen (2 mL, 12 intra-articular injections over 6 months)
Study: 19397687
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL, 12 intra-articular injections over 6 months)
Study: 12067865
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg iv just prior to induction of anesthesia
Study: 70931
Drug: Zinc sulphate,
Normalized name: Zinc sulphate, anhydrous
DrugBank: Zinc sulfate (DB09322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc sulphate, 0.6 g daily for 12 weeks (some patients treated for 4 or 8 weeks)
Study: 30930573
Drug: Ultrasound phonophoresis
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound phonophoresis therapy with Lofnac Gel (diclofenac and methyl salicylate)
Study: 30930573
Drug: Ultrasound phonophoresis
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound phonophoresis therapy with Lofnac Gel
Study: 21136267
Drug: Intra-umbilical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-umbilical oxytocin 100 IU diluted in 30 ml of saline
Study: 9338642
Drug: Pulsatile flow
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile flow at pump flow rates of 0.6, 1.2, and 2.4 L x m2 x min(‐1)
Study: 9338642
Drug: Nonpulsatile flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpulsatile flow at pump flow rates of 0.6, 1.2, and 2.4 L x m2 x min(‐1)
Study: 3318993
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rimexolone
Study: 3318993
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rimexolone
Study: 3318993
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rimexolone
Study: 28729473
Drug: Manual oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual oxygen titration
Study: 16219013
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily plus a diet providing an energy deficit of 500 kcal/day